Poseida Therapeutics Inc (PSTX)
2.98
+0.04
(+1.36%)
USD |
NASDAQ |
Jul 05, 16:00
2.995
+0.02
(+0.50%)
After-Hours: 20:00
Poseida Therapeutics Research and Development Expense (Annual): 156.77M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 156.77M |
| December 31, 2022 | 152.90M |
| December 31, 2021 | 136.73M |
| December 31, 2020 | 103.52M |
| Date | Value |
|---|---|
| December 31, 2019 | 60.39M |
| December 31, 2018 | 30.88M |
| December 31, 2017 | 19.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
60.39M
Minimum
2019
156.77M
Maximum
2023
122.06M
Average
136.73M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Cartesian Therapeutics Inc | 71.84M |
| Biomea Fusion Inc | 102.55M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |